Ketamine Clinic MSO Counsel for Operators and Investors
We structure MSOs and friendly-PC arrangements that hold up under state corporate-practice-of-medicine review, DEA scrutiny, and investor diligence.
Ketamine clinics sit at the intersection of three regulatory regimes that do not always agree with each other. The DEA treats racemic ketamine as a Schedule III controlled substance with specific registration, storage, and recordkeeping obligations. State medical boards enforce the corporate practice of medicine doctrine, which in roughly thirty states limits who can own a clinical entity and how non-clinical capital can participate in revenue. And state pharmacy, telehealth, and anesthesia rules each add their own overlay, especially for at-home and compounded ketamine programs. An MSO structure can work across all of it, but only if the agreements are drafted to the specific state the clinic operates in.
Howard East is a ketamine clinic MSO law firm representing founders, management services organizations, and the investors who back them. Our work focuses on structuring the friendly-PC and MSO relationship so the clinical entity stays physician-owned and physician-controlled on paper and in practice, while the MSO captures the administrative, marketing, and capital-raising upside the deal depends on. We draft the MSAs, the equity documents, and the roll-up purchase agreements, and we tell clients when a state CPOM regime will not tolerate what they are trying to do.
Ketamine Clinic Fundamentals and Valuations
The U.S. ketamine clinic market is fragmented, growing roughly nine percent per year, and actively being rolled up by multi-state operators and private-equity-backed platforms. Standalone clinics typically run on a mix of IV infusion, intramuscular dosing, and Spravato (esketamine) for insurance-reimbursed indications, with cash-pay infusions driving margin and Spravato driving payer revenue. Valuations turn on payer mix, provider productivity, protocol compliance, and whether the clinic has a defensible MSO structure that survives diligence.
- Typical clinic revenue mix: cash-pay IV infusions, IM and troche programs, Spravato reimbursement, and integration therapy add-ons
- Multiples in recent transactions have ranged widely, with single-clinic deals closing on EBITDA multiples and multi-clinic platforms closing on revenue multiples tied to growth
- Buyer types: regional roll-ups, behavioral health platforms, psychedelic-adjacent companies, and standalone strategic operators
- Common deal structures: asset purchases, reverse triangular mergers, and equity rollover with earnouts tied to provider retention
- Diligence killers: non-compliant MSO agreements, unregistered DEA locations, Spravato REMS enrollment gaps, and provider 1099 misclassification
Ketamine clinic MSO valuation work is inseparable from its legal structure. A clinic with a clean friendly-PC and a defensible MSA trades at a materially different multiple than one with a layperson on the cap table of the clinical entity.
Legal Structures for Ketamine Clinic MSOs
In CPOM states, the clinical entity that employs the physicians, nurses, and CRNAs delivering ketamine must be owned by licensed clinicians. Everything else, including the real estate, billing infrastructure, marketing, non-clinical employees, and capital, lives in a separate MSO owned by the investors. The two entities are connected by a management services agreement that has to allocate control, revenue, and risk in a way that a state medical board would not characterize as indirect lay ownership of a clinical practice.
- Friendly-PC model: a licensed physician owns the professional corporation (PC or PLLC) that employs clinical staff; the MSO contracts with the PC for administrative services
- Stock transfer restriction agreements: lock in the physician owner of the PC so the MSO can swap the nominee physician without renegotiating the entire structure
- Fee models: fixed-fee, cost-plus, and percentage-of-collections each carry different CPOM and anti-kickback exposure
- Multi-state platforms: each state gets its own PC and its own MSA, tuned to that state CPOM rules, fee-splitting restrictions, and pharmacy regulations
- Spravato and payer-contract carveouts: the PC typically holds the provider NPI and payer contracts, while the MSO bills on behalf of the PC under a delegated billing arrangement
We draft these structures to survive both day-one board scrutiny and day-1,000 acquisition diligence, because the buyer counsel will read every one of these documents looking for a reason to retrade.
For background on the federal regulatory framework, see the DEA registration rules under 21 CFR Part 1301, the SAMHSA guidance on behavioral health, and the DEA Federal Register notices on telemedicine rulemaking for ketamine clinic MSO operators.
Regulatory and Compliance Considerations
Ketamine clinics answer to the DEA, state medical boards, state pharmacy boards, and, if they are compounding or running at-home programs, state controlled-substance regulators as well. A ketamine clinic MSO compliance program that assumes it is just Schedule III is incomplete. The DEA telemedicine flexibilities that allowed at-home ketamine prescribing during COVID were operating on extended rules, and the 2025 proposed permanent rule reshaped what is allowed going forward.
- DEA registration: each physical location that stores or administers ketamine needs its own DEA registration under 21 CFR Part 1301
- Storage and recordkeeping: locked, permanent storage, initial and biennial inventory, and DEA Form 222 for Schedule II if the clinic also handles other scheduled drugs
- Telehealth: the 2025 DEA proposed rule on special telemedicine registrations changes what at-home ketamine programs can do without an in-person exam
- Compounding: use of compounded ketamine troches or nasal sprays invokes 503A and 503B pharmacy rules and FDA enforcement discretion policies
- Spravato REMS: clinics dispensing esketamine must enroll in the REMS program and observe the two-hour post-administration monitoring requirement
- State medical board protocols: several states have adopted ketamine-specific protocol requirements covering screening, monitoring, and informed consent
Howard East handles the compliance build alongside the corporate structure, because the two are the same problem. A clinic MSO structure is only defensible if the underlying clinical operation is.
Due Diligence and Common Risk Areas
Whether we are representing a ketamine clinic MSO selling to a platform or a platform buying one, the diligence checklist is the same, and the risk areas show up in roughly the same places every time. Most of the problems we find in diligence could have been prevented with two hours of planning at the clinic formation.
- MSO agreement: is the fee fair market value, documented by an appraisal, and not structured as a percentage of clinical revenue in a state that prohibits it
- Friendly-PC documentation: does the physician owner of the PC actually hold the shares, have a transfer restriction agreement, and file state annual reports
- Provider classification: are the clinical providers employees of the PC, 1099 contractors, or misclassified, the last of which is a common retrade lever
- DEA registrations: one per location, current, and matching the legal entity that holds the lease
- Payer contracts and credentialing: who holds the contract, what happens on a change of control, and are any contracts assignable
- Informed consent, protocol, and chart quality: sampled charts should match the clinic written protocol
A clean diligence binder is not an accident. It is the product of a clinic that was structured correctly from day one and kept its paperwork current.
Key MSA and Friendly-PC Contract Provisions
The ketamine clinic MSO management services agreement is the single most scrutinized document in any transaction. State medical boards look at it to assess CPOM compliance. Buyers look at it to assess the durability of the platform. And lenders look at it to understand where their cash flow comes from. The drafting choices we make up front determine all three outcomes.
- Scope of services: specific, enumerated, and strictly non-clinical, including billing, collections, marketing, HR, IT, space, and supplies
- Fee methodology: tied to fair market value for the services provided, supported by a valuation, and sized to the state tolerance
- Term, termination, and transition: physician PC owner cannot be indentured, and MSO needs adequate notice and a wind-down runway
- Restrictive covenants: non-competes enforceable against the physician owner under state law, not against the PC itself
- Recordkeeping and ownership: clinical records owned by the PC, business records by the MSO, mutual access on defined terms
- Indemnification and insurance: PC carries malpractice, MSO carries E and O and general liability, both are additional insureds as appropriate
Drafted well, the MSA is both a compliance artifact and a business document. It tells a regulator the clinic is physician-controlled and tells a buyer the cash flow is assignable.
Howard East Ketamine Clinic MSO Services
We represent ketamine clinic founders, MSOs, and the investors backing them on the full lifecycle of the business, from formation through roll-up exit. The work is transactional and regulatory in roughly equal measure.
- Formation: friendly-PC and MSO entity setup, operating agreements, stock transfer restriction agreements, and initial MSAs
- Multi-state expansion: state-by-state CPOM and fee-splitting analysis, PC formation, and MSA adaptation
- Capital raises: SAFEs, convertible notes, priced rounds, and the disclosures investors in healthcare-services businesses expect to see
- M and A: sell-side representation for clinic owners, buy-side representation for platforms and PE-backed acquirers, and the diligence and structuring work that precedes both
- Ongoing compliance: DEA registration support, protocol review, Spravato REMS compliance, and coordination with state medical board counsel
- Disputes: friendly-PC and MSO disagreements, investor disputes, and partnership separations
Every engagement starts with a review of what the client already has in place, because the most efficient path forward almost always involves fixing something rather than starting from scratch.
Why Legal Counsel Matters for Ketamine Clinics
Ketamine is a high-margin, high-regulation business. The clinics that survive the next round of enforcement will be the ones that took their structure seriously from the start. The clinics that get written up, sued, or retraded in diligence are almost always the ones that used a generic LLC template and a non-specialized MSA pulled off a form site.
- CPOM enforcement is escalating in California, New York, Texas, Illinois, and Washington, the states where most ketamine clinic investment is concentrated
- The DEA telemedicine rulemaking is reshaping what at-home ketamine looks like, and clinics that anchored their business model to the old flexibilities are exposed
- Private-equity diligence in this space is sophisticated and unforgiving, and buyers retrade on CPOM defects
- A well-drafted MSA and friendly-PC stack is a durable moat; a sloppy one is a ticking clock
The cost of getting this right up front is trivial compared to the cost of fixing it under diligence pressure or regulatory review.
Speak with an Attorney About Your Ketamine Clinic
If you operate a ketamine clinic, are building an MSO platform, or are evaluating an acquisition in the space, Howard East can help you get the structure right the first time.
Request a Confidential Call
Tell us about your ketamine clinic or MSO platform. We review inquiries and respond within one business day.